

| | | | | |
|---|---|----------------------------------|--------------------------|-----------|
| Name of the Issue: Anthem Biosciences Limited | | Last updated on: August 15, 2025 | | 31-Jul-25 |
| 1 | Type of Issue | | Initial Public offer | |
| 2 | Offer Size (Rs. Mn) | | 33,950.00 | |
| | Fresh Issue Size (Rs. Mn) | | - | |
| | Offer for Sale (Rs Mn) | | 33,950.00 | |
| | *Source: Prospectus for the offer dated July 16 2025 | | | |
| 3 | Grade of issue along with name of the rating agency | | | |
| | Name | NA | | |
| | Grade | NA | | |
| 4 | Subscription Level (Number of times) | | 47.50 | |
| | * excluding Eligible employee and Eligible shareholder reservation and after removing multiple and duplicate bids and Source: Post Offer Report dated July 23, 2025 | | | |
| 5 | QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges | | | |
| | Particulars | | % | |
| | (i) On Allotment in the offer ⁽¹⁾ | | 2.11 | |
| | (ii) at the end of the 1st Quarter immediately after the listing of the issue (period ended September 30, 2025) * | | Not Available | |
| | (iii) at the end of 1st FY (March 31, 2026)* | | Not Available | |
| | (iv) at the end of 2nd FY (March 31, 2027)* | | Not Available | |
| | (v) at the end of 3rd FY (March 31, 2028)* | | Not Available | |
| | *QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed. | | | |
| | (1) Source: Post offer report and BSE website | | | |
| 6 | Financials of the issuer | | | |
| | Parameters | | (Rs. in Mn) | |
| | 1st FY (March 31, 2026)* | | 2nd FY (March 31, 2027)* | |
| | Income from operations | | Not Available | |
| | Net Profit for the period | | Not Available | |
| | Paid-up equity share capital | | Not Available | |
| | Reserves excluding revaluation reserves | | Not Available | |
| | *Financials not available as reporting for the relevant years has not been completed. | | | |
| 7 | Trading Status | | | |
| | The equity shares of Anthem Biosciences Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges") | | | |
| | The equity shares have not been suspended or delisted. | | | |
| | Particulars | | Status | |
| | (i) at the end of 1st FY (March 31, 2026)* | | Not Available | |
| | (ii) at the end of 2nd FY (March 31, 2027)* | | Not Available | |
| | (iii) at the end of 3rd FY (March 31, 2028)* | | Not Available | |
| | * Trading status not disclosed as the relevant fiscal years have not been completed. | | | |
| 8 | Change in Directors of Issuer from the disclosures in the offer document [#] | | | |
| | Particulars | | Name of Director | |
| | (i) at the end of 1st FY (March 31, 2026)* | | NA | |
| | (ii) at the end of 2nd FY (March 31, 2027)* | | NA | |
| | (iii) at the end of 3rd FY (March 31, 2028)* | | NA | |
| | * Relevant fiscal years have not been completed. | | | |
| | # Source - Stock Exchange website | | | |
| 9 | Status of implementation of project/ commencement of commercial production | | | |
| | (i) as disclosed in the offer document | | Not applicable* | |
| | (ii) Actual implementation | | Not applicable* | |
| | (iii) Reasons for delay in implementation, if any | | Not applicable* | |
| | * Company did not undertake any implementation of project hence the same is not applicable | | | |
| 10 | Status of utilization of issue proceeds | | | |
| | The objects of the Offer were to (i) to carry out the Offer for Sale of 59,575,319 Equity Shares of face value of ₹ 2 each by the Selling Shareholders aggregating to ₹ 33,950.00 million; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. | | | |
| 11 | Comments of monitoring agency, if applicable | | | |
| | (i) Comments on use of funds | | NA | |
| | (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the | | | |
| | (iii) Any other reservations expressed by the monitoring agency about the end use of funds | | | |

12

Pricing Data

Designated Stock Exchange

BSE

Offer Price (Rs.)

570.00

Listing Date

21-Jul-25

| Price parameters | At close of listing day (July 21, 2025) | Close of 30th calendar day from listing day ⁽²⁾ (August 20, 2025) | Close of 90th calendar day from listing day ⁽³⁾ (October 19, 2025) | As at the end of the 1st FY after the listing of the issue (31st March, 2026) | | |
|------------------------------------|---|---|--|---|-------------------------|---------------------|
| | | | | ⁽¹⁾⁽⁴⁾ | | |
| | | | | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on NSE ⁽⁵⁾ | 840.95 | Not Available | Not Available | Not Available | Not Available | Not Available |
| Nifty ⁽⁵⁾ | 25,453.40 | Not Available | Not Available | Not Available | Not Available | Not Available |
| Sectoral Index ⁽⁶⁾ | Not comparable to any of the available sectoral indices | | | Not comparable to any of the available sectoral indices | | |
| Price parameters | As at the end of the 2nd FY after the listing of the issue (31st March, 2027) ⁽¹⁾⁽⁴⁾ | | | As at the end of the 3rd FY after the listing of the issue (31st March, 2028) ⁽¹⁾⁽⁴⁾ | | |
| | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on NSE ⁽⁵⁾ | NA | NA | NA | NA | NA | NA |
| Nifty ⁽⁵⁾ | NA | NA | NA | NA | NA | NA |
| Sectoral Index ⁽⁶⁾ | Not comparable to any of the available sectoral indices | | | Not comparable to any of the available sectoral indices | | |

Source: NSE website

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) 30th calendar day is taken as listing date plus 29 calendar days

(3) 90th calendar day is taken as listing date plus 89 calendar days

(4) High and Low based on intra day prices

(5) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.

(6) Comparable Sectoral index is not available

13

Basis for Offer Price

| Accounting ratio | As disclosed in the offer document ⁽¹⁾ | | At the end of 1st FY (March 31, 2026) ⁽³⁾ | At the end of 2nd FY (March 31, 2027) ⁽³⁾ | At the end of 3rd FY (March 31, 2028) ⁽³⁾ |
|------------------------------------|---|-----------|---|--|---|
| EPS (₹) | Issuer: | | | | |
| | Consolidated (Basic) | 8.07 | Not Available | Not Available | Not Available |
| | Consolidated (Diluted) | 8.04 | Not Available | Not Available | Not Available |
| | Peer Group: (Diluted) | | | | |
| | Syngene International Limited | 12.34 | Not Available | Not Available | Not Available |
| | Sai Life Sciences Limited | 8.61 | Not Available | Not Available | Not Available |
| | Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals) | 10.45 | Not Available | Not Available | Not Available |
| | Divi's Laboratories Limited | 82.53 | Not Available | Not Available | Not Available |
| | Industry Avg: | 28.48 | Not Available | Not Available | Not Available |
| | Issuer: | | | | |
| Price to Earnings Ratio (P/E) | Consolidated (Consolidated) | 70.9 | Not Available | Not Available | Not Available |
| | Peer Group (Consolidated) | | | | |
| | Syngene International Limited | 51.54 | Not Available | Not Available | Not Available |
| | Sai Life Sciences Limited | 92.18 | Not Available | Not Available | Not Available |
| | Cohance Lifesciences Limited (Formerly Suven | 97.29 | Not Available | Not Available | Not Available |
| | Divi's Laboratories Limited | 83.22 | Not Available | Not Available | Not Available |
| | Industry Avg: | 81.06 | Not Available | Not Available | Not Available |
| | Issuer: | | | | |
| | Consolidated | 20.82 | Not Available | Not Available | Not Available |
| | Peer Group: (Consolidated) | | | | |
| Return on Net Worth (%) | Syngene International Limited | 11.05 | Not Available | Not Available | Not Available |
| | Sai Life Sciences Limited | 10.96 | Not Available | Not Available | Not Available |
| | Cohance Lifesciences Limited (Formerly Suven | 13.61 | Not Available | Not Available | Not Available |
| | Divi's Laboratories Limited | 15.35 | Not Available | Not Available | Not Available |
| | Industry Avg: | 12.74 | Not Available | Not Available | Not Available |
| | Issuer: | | | | |
| | Consolidated | 43.1 | Not Available | Not Available | Not Available |
| | Peer Group: (Consolidated) | | | | |
| | Syngene International Limited | 117.42 | Not Available | Not Available | Not Available |
| | Sai Life Sciences Limited | 102.12 | Not Available | Not Available | Not Available |
| NAV per Equity Share (₹ per share) | Cohance Lifesciences Limited (Formerly Suven | 72.31 | Not Available | Not Available | Not Available |
| | Divi's Laboratories Limited | 564.87 | Not Available | Not Available | Not Available |
| | Industry Avg: | 214.18 | Not Available | Not Available | Not Available |
| | Issuer: | | | | |
| | Consolidated | 18,445.53 | Not Available | Not Available | Not Available |
| | Peer Group: (Consolidated) | | | | |
| | Syngene International Limited | 36,424.00 | Not Available | Not Available | Not Available |
| | Sai Life Sciences Limited | 16,945.70 | Not Available | Not Available | Not Available |
| | Cohance Lifesciences Limited (Formerly Suven | 11,975.80 | Not Available | Not Available | Not Available |
| | Divi's Laboratories Limited | 93,600.00 | Not Available | Not Available | Not Available |
| | Industry Avg: | 39,736 | Not Available | Not Available | Not Available |

| | | | | |
|----------------------------|--|--------------|---------------|---------------|
| EV/ Operating EBITDA Ratio | Issuer: | | | |
| | Consolidated (Basic) | 45.91 | Not Available | Not Available |
| | Peer Group (Consolidated) | | | |
| | Syngene International Limited | 23.93 | Not Available | Not Available |
| | Sai Life Sciences Limited | 39.95 | Not Available | Not Available |
| | Cohance Lifesciences Limited (Formerly Suven | 68.44 | Not Available | Not Available |
| | Divi's Laboratories Limited | 60.07 | Not Available | Not Available |
| | Industry Avg: | 48.10 | Not Available | Not Available |

(1)*Source: Prospectus for the offer dated July 16, 2025
(2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges
(3) Information not provided as the relevant fiscal year has not completed
Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:
1. P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on National Stock Exchange of India Limited ("NSE") as on July 7, 2025 divided by the diluted earnings per share for the Fiscal ended March 31, 2025.
2. EV/ Operating EBITDA ratio for the listed industry peers has been computed as the market capitalization of the industry peers based on the closing market price of equity shares on NSE on July 7, 2025 plus the net debt as on March 31, 2025 divided by Operating EBITDA for the Fiscal ended March 31, 2025.
3. Return on Net Worth (%) = Ratio of Profit /(loss) for the year attributable to owners of the company for the Fiscal to Net Worth as of the last day of the relevant Fiscal. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non controlling interest.
4. Net Asset Value per Equity Share = Net worth / Weighted average number of Equity Shares outstanding during the year. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non controlling interest.

Any other material information

14

| Date | Announcement |
|----------------|---|
| 21 July 2025 | Listing of Equity Shares of Anthem Biosciences Ltd |
| 21 July 2025 | Intimation of continuation of Ms. Divya Prasad as the Compliance Officer of Anthem Biosciences Limited pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), 2015 |
| 21 July 2025 | Closure of Trading Window |
| 21 July 2025 | Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 |
| 21 July 2025 | Intimation of continuation of Kflin Technologies Limited as the Registrar and Share Transfer Agent of Anthem Biosciences Limited Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), 2015 - Names of the key management personnel of the company who are authorised to determine the materiality of an event or information and for the purpose of making disclosure to the stock exchanges under Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 |
| 21 July 2025 | Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025 |
| 08 August 2025 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 08 August 2025 | Board Meeting Outcome - Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025 |
| 13 August 2025 | Press release on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2025. |
| 13 August 2025 | Investor Presentation on Unaudited Consolidated Financial Statement for the Quarter ended June 30, 2025 |
| 13 August 2025 | Newspaper Advertisement - Unaudited Consolidated and Standalone Financial Results for the Quarter ended June 30, 2025 |
| 13 August 2025 | Newspaper advertisement confirming dispatch of Postal Ballot Notice |
| 13 August 2025 | Earnings Call Transcripts for the Quarter ended June 30, 2025 |

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.